<DOC>
	<DOC>NCT00636259</DOC>
	<brief_summary>This study provides compassionate use of bicalutamide (Casodex) at a 150-mg dose for subjects with prostate cancer prior to it becoming commercially available. The patient will receive bicalutamide 150-mg as long as the physician feels that the subject is benefiting from this therapy and safety information is provided regularly to AstraZeneca. Treatment will be discontinued after bicalutamide 150-mg becomes commercially available.</brief_summary>
	<brief_title>Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Patients with adenocarcinoma of the prostate Subjects with locally advanced, and/or metastatic prostate cancer for whom surgical castration or other medical interventions are not considered appropriate or acceptable Any known history of abnormal liver function tests Any severe concomitant condition that would make it undesirable, in the clinician's opinion, for the subject to participate in the trial. Known hypersensitivity to bicalutamide or any of the components found in bicalutamide</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Casodex</keyword>
</DOC>